Bank of New York Mellon Corp lifted its position in Heron Therapeutics Inc (NASDAQ:HRTX) by 7.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 299,384 shares of the biotechnology company’s stock after acquiring an additional 19,966 shares during the period. Bank of New York Mellon Corp owned approximately 0.42% of Heron Therapeutics worth $11,632,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. State Board of Administration of Florida Retirement System grew its stake in shares of Heron Therapeutics by 33.5% in the second quarter. State Board of Administration of Florida Retirement System now owns 25,380 shares of the biotechnology company’s stock valued at $986,000 after buying an additional 6,370 shares in the last quarter. Rhumbline Advisers boosted its position in Heron Therapeutics by 20.7% during the second quarter. Rhumbline Advisers now owns 59,401 shares of the biotechnology company’s stock worth $2,308,000 after purchasing an additional 10,173 shares during the period. Sei Investments Co. bought a new position in Heron Therapeutics during the second quarter worth $1,149,000. C WorldWide Group Holding A S boosted its position in Heron Therapeutics by 85.1% during the second quarter. C WorldWide Group Holding A S now owns 211,012 shares of the biotechnology company’s stock worth $8,198,000 after purchasing an additional 97,002 shares during the period. Finally, State of Wisconsin Investment Board boosted its position in Heron Therapeutics by 20.4% during the second quarter. State of Wisconsin Investment Board now owns 66,200 shares of the biotechnology company’s stock worth $2,572,000 after purchasing an additional 11,200 shares during the period.

In other news, Director Kevin C. Tang sold 2,695,000 shares of Heron Therapeutics stock in a transaction on Wednesday, September 12th. The stock was sold at an average price of $35.75, for a total transaction of $96,346,250.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, President Robert Rosen sold 225,000 shares of Heron Therapeutics stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $38.98, for a total value of $8,770,500.00. Following the sale, the president now directly owns 132,109 shares of the company’s stock, valued at approximately $5,149,608.82. The disclosure for this sale can be found here. Insiders have sold 3,085,469 shares of company stock valued at $111,612,708 in the last three months. Insiders own 16.20% of the company’s stock.

HRTX opened at $31.40 on Monday. Heron Therapeutics Inc has a fifty-two week low of $14.40 and a fifty-two week high of $42.90. The firm has a market cap of $2.44 billion, a PE ratio of 8.60 and a beta of 1.44.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.54) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.14. Heron Therapeutics had a negative return on equity of 112.35% and a negative net margin of 411.41%. The company had revenue of $17.28 million during the quarter, compared to the consensus estimate of $12.82 million. During the same quarter last year, the firm earned ($0.80) earnings per share. The company’s revenue was up 103.1% on a year-over-year basis. research analysts forecast that Heron Therapeutics Inc will post -2.2 EPS for the current fiscal year.

A number of equities analysts have commented on the stock. Evercore ISI lifted their price objective on shares of Heron Therapeutics from $56.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, June 21st. Leerink Swann lifted their price objective on shares of Heron Therapeutics to $46.00 and gave the stock an “outperform” rating in a research report on Friday, June 22nd. Oppenheimer lifted their price objective on shares of Heron Therapeutics from $34.00 to $50.00 and gave the stock an “outperform” rating in a research report on Friday, June 22nd. ValuEngine cut shares of Heron Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 2nd. Finally, Cantor Fitzgerald lifted their price objective on shares of Heron Therapeutics from $40.00 to $50.00 and gave the stock an “overweight” rating in a research report on Thursday, July 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the company’s stock. Heron Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $50.50.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Story: How Short Selling Works

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.